179554-06-4Relevant articles and documents
POLYCYCLIC COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND OR THE COMPOSITION
-
Page/Page column 300-301, (2020/11/03)
Specific polycyclic compounds, a material for an organic electroluminescence device comprising said specific polycyclic compound, an organic electroluminescence device comprising said specific polycyclic compound, an electronic equipment comprising said organic electroluminescence device, a process for preparing said polycyclic compounds, and the use of said polycyclic compounds in an organic electroluminescence. (Formula I) (I)
THERAPEUTIC COMPOUNDS
-
Paragraph 0394; 0395, (2018/08/30)
The invention provides compounds of formula Ia′, Ib′, Ic′, and Id′: and pharmaceutically acceptable salts thereof, wherein the variables A, R6, R7, R8, R9, Rx, L, X, Y, and Z have the meaning as described herein. The compounds are useful for reducing endoplasmic reticulum stress and for producing analgesia in an animal.
Imine compound, novel catalyst for olefin polymerization, and method for producing olefin polymer
-
, (2016/10/09)
Disclosed is a compound represented by the following general formula (1). In the formula, X represents a nitrogen atom, Y represents a nitrogen atom or a phosphorous atom, R5 and R6 independently represent C1-30 hydrocarbon groups which may contain a hydrogen atom or a hetero atom, and at least one of R5 and R6 is a hydrocarbon group having two or more hetero atom-containing groups, and R1 to R4 independently represent a hydrogen atom, a halogen atom or a C1-20 hydrocarbon group which may contain a hetero atom. A plurality of groups selected from the R1 to the R4 may be connected with one another to form aliphatic rings, aromatic rings or heterocycles containing hetero atoms selected from oxygen, nitrogen and sulfur. At the time, the number of ring members is 5-8, and the ring may have a substituent.
Imidazol derivatives
-
, (2008/06/13)
This invention relates to novel imidazole derivatives of formula a STR1 and pharmaceutically acceptable salts of these compounds, wherein R1, R2, R3, R5, R7 and R8 are as disclosed herein.
